NCT04566393
Available
不适用
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures27 个研究点 分布在 1 个国家开始时间: 2020年9月28日最近更新:
适应症Pancreatic CancerSmall Bowel CancerColorectal CancerMelanomaNon Small Cell Lung CancerThyroid CancerBladder CancerHead and Neck CancerGastric CancerEsophageal CancerCholangiocarcinomaOvarian CancerHepatocellular CarcinomaGlioblastomaMAPK Gene MutationKRAS Activating MutationBRAF Gene MutationNRAS Gene MutationHRAS Gene MutationMEK MutationERK Mutation
概览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- xCures
- 试验地点
- 27
概览
简要总结
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.
Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main Inclusion Criterion:
- •1\. Patient has a MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations.
- •Other Inclusion Criteria:
- •In the opinion of the treating physician, the patient has exhausted or has inadequate response to available anti-cancer treatments.
- •In the opinion of the treating physician, the patient has adequate organ function to tolerate ulixertinib as defined in section 6.1
- •Male or female patients aged ≥ 12 years.
- •Patient must be able to swallow and retain orally administered medication.
- •Note: Ulixertinib is primarily absorbed in the duodenum and therefore patients with any prior stomach or duodenal resection should be evaluated with that understanding.
- •For females, evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal patients.
- •Highly effective contraception for both male and female patients throughout the treatment and for at least 4 months after last treatment administration. In patients under the age of 18, who are not sexually active, abstinence is an acceptable form.
排除标准
- •Patient is already participating in or qualifies for and is able to enroll in a clinical trial of ulixertinib (BVD-523).
- •Patient has received systemic therapy with an investigational agent within 5 half-lives or 14 days prior to starting ulixertinib treatment, whichever is shorter.
- •Patient has received radiotherapy within 14 days prior to the first dose of ulixertinib treatment other than for the allowable treatment of symptomatic bone metastasis.
- •A history of current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
- •Current evidence of uncontrolled, significant intercurrent illness that would, in the treating physician's judgment, contraindicate the patient's treatment with ulixertinib due to safety concerns.
- •Patients who, in the opinion of the treating physician, have not fully recovered from recent major surgery to a sufficient extent to tolerate treatment with ulixertinib.
- •Known hypersensitivity to ulixertinib or any component in its formulation.
- •Patients taking prohibited medications as described in current Investigator's Brochure.
- •Note: Patients who require treatment with Drugs that are strong inhibitors or inducers of CYP1A2, CYP2D6, and CYP3A4 (see Appendix 3) were excluded from the FIH study of ulixertinib and should be discussed with xCures to review if any potential benefits outweigh the potential risks.
- •Patient is actively breastfeeding.
研究者
研究点 (27)
Loading locations...
相似试验
Available
不适用
Expanded Access to UpadacitinibNCT04159597AbbVie
Temporarily Not Available
不适用
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Castration-Resistant Prostatic CancerNCT06033001Lantheus Medical Imaging
No Longer Available
不适用
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) MutationsNCT03409081Astellas Pharma Global Development, Inc.
No Longer Available
不适用
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)Colorectal CancerNCT06195514Takeda
Available
不适用
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie